Ivabradine

Ivabradine, the active ingredient in Ivabradine, is a selective If channel inhibitor presented as a tablet for oral use. It treats chronic stable angina and heart failure with reduced ejection fraction in adults.

GNH USA supplies Ivabradine as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradine acts on the cardiac sinus node to lower heart rate, benefiting conditions where heart‑rate reduction improves outcomes. - Chronic stable angina: reduces the frequency of angina attacks by decreasing myocardial oxygen demand. - Heart failure with reduced ejection fraction: improves symptoms and lowers hospitalization risk by controlling heart rate. - Patients intolerant to beta‑blockers: provides heart‑rate control without beta‑adrenergic blockade.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Bradycardia: heart rate slower than intended. - Visual disturbances (phosphenes): transient luminous phenomena. - Headache. - Dizziness. - Fatigue.

Serious or Rare Side Effects: - Symptomatic bradycardia requiring medical intervention. - Atrial fibrillation or other arrhythmias. - Severe hypotension. - Persistent visual impairment. - Heart block requiring pacing.

Careful assessment and monitoring are required before and during therapy. - Heart‑rate monitoring: obtain baseline rate and reassess after dose changes. - Hepatic impairment: avoid in severe liver disease; adjust if moderate. - CYP3A4 inhibitors: use caution with strong inhibitors that may raise plasma levels. - Concomitant bradycardic agents: avoid combining with beta‑blockers or digoxin unless clinically justified. - Pregnancy and lactation: safety unknown; prescribe only if benefits outweigh risks. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Ivabradine may interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can markedly increase Ivabradine exposure. - Concomitant bradycardic agents (beta‑blockers, digoxin): may cause excessive heart‑rate reduction. - Other If channel inhibitors: additive effect on heart‑rate lowering.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil): may modestly raise levels. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Antihypertensives: monitor blood pressure for additive hypotensive effect.